Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Civasta (melatonin) 2 mg prolonged-release tablets

Active Ingredient:
melatonin
Company:  
Neuraxpharm UK Ltd See contact details
ATC code: 
N05CH01
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) HCP Med Info
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 09 Nov 2022
{pdf} View or print the patient leaflet as PDF

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on {phone} 0800 198 5000. The product code(s) for this leaflet is: PL 49718/0091.

{printer} Print patient leaflet as text only

Civasta (melatonin) 2 mg prolonged-release tablets

Package Leaflet: Information for the patient

Civasta 2 mg prolonged-release tablets

melatonin

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Civasta is and what it is used for
2. What you need to know before you take Civasta
3. How to take Civasta
4. Possible side effects
5. How to store Civasta
6. Contents of the pack and other information

1. What Civasta is and what it is used for

The name of your medicine is Civasta 2 mg prolonged-release tablets and is referred to as Civasta throughout this leaflet.

The active substance of Civasta, melatonin, belongs to a natural group of hormones produced by the body.

Civasta is used on its own for the short-term treatment of primary insomnia (persistent difficulty in getting to sleep or staying asleep, or poor quality of sleep) in patients aged 55 years and older. ‘Primary’ means that the insomnia does not have any identified cause, including any medical, mental or environmental cause.

2. What you need to know before you take Civasta
Do not take Civasta
  • if you are allergic to melatonin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before taking Civasta:

  • If you suffer from liver or kidney problems. No studies on the use of this medicine in people with liver or kidney diseases have been performed; you should speak to your doctor before taking Civasta as its use is not recommended.
  • If you have been told by your doctor that you have an intolerance to some sugars.
  • If you have been told you suffer from an autoimmune disease (where the body is ‘attacked’ by its own immune system). No studies on the use of this medicine in people with auto- immune diseases have been performed; therefore, you should speak to your doctor before taking Civasta as its use is not recommended.
  • This medicine can make you feel drowsy; you should be careful if the drowsiness affects you as it may impair your ability to perform tasks such as driving.
  • Smoking may make this medicine less effective, because the components of tobacco smoke can increase the breakdown of melatonin by the liver.

Children and adolescents

Do not give this medicine to children between the ages of 0 to 18 years as it has not been tested and its effects are unknown. Another medicine containing melatonin may be more appropriate for administration to children between the ages of 2 to 18 - please ask your doctor or pharmacist for advice.

Other medicines and Civasta

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

These medicines include:

  • Fluvoxamine (used for the treatment of depression and obsessive compulsive disorder), psoralens (used in the treatment of skin disorders e.g. psoriasis), cimetidine (used in the treatment of stomach problems such as ulcers), quinolones and rifampicin (used in the treatment of bacterial infections), oestrogens (used in contraceptives or hormone replacement therapy) and carbamazepine (used in the treatment of epilepsy).
  • Adrenergic agonists/antagonists (such as certain types of medicines used to control blood pressure by constricting blood vessels, nasal decongestants, blood pressure lowering medicines), opiate agonists/antagonists (such as medicinal products used in the treatment of drug addiction), prostaglandin inhibitors (such as nonsteroidal anti-inflammatory medicines), antidepressant medication, tryptophan and alcohol.
  • Benzodiazepines and non-benzodiazepine hypnotics (medicines used to induce sleep such as zaleplon, zolpidem and zopiclone)
  • Thioridazine (for the treatment of schizophrenia) and imipramine (for the treatment of depression).

Civasta with food, drink and alcohol

Take Civasta after you have eaten. Do not drink alcohol before, during or after taking Civasta, because it reduces the effectiveness of the medicine.

Pregnancy and breast-feeding

Do not take Civasta if you are pregnant, think you may be pregnant, trying to become pregnant or breast-feeding. Ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

This medicine may cause drowsiness. If you are affected, you should not drive or operate machinery. If you suffer from continued drowsiness, then you should consult your doctor.

Civasta contains lactose monohydrate

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Civasta

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is one tablet (2 mg) taken daily by mouth, after food, 1 - 2 hours before bedtime. This dosage may be continued for up to thirteen weeks.

You should swallow the tablet whole. The tablets should not be crushed or cut in half.

If you take more Civasta than you should

If you have accidentally taken too much of your medicine, contact your doctor or pharmacist as soon as possible.

Taking more than the recommended daily dose may make you feel drowsy.

If you forget to take Civasta

If you forget to take your tablet, take it as soon as you remember, before going to sleep, or wait until it is time to take your next dose, then go on as before.

Do not take a double dose to make up for a forgotten dose.

If you stop taking Civasta

There are no known harmful effects if treatment is interrupted or ended early. The use of this medicine is not known to cause any withdrawal effects after treatment completion.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you experience any of the following serious side effects, stop taking this medicine and contact your doctor immediately:

Uncommon: (may affect up to 1 in 100 people)

  • Chest pain

Rare: (may affect up to 1 in 1000 people)

  • Loss of consciousness or fainting
  • Severe chest pain due to angina
  • Feeling your heartbeat
  • Depression
  • Visual impairment
  • Blurred vision
  • Disorientation
  • Vertigo (a feeling of dizziness or “spinning”)
  • Presence of red blood cells in the urine
  • Reduced number of white blood cells in the blood
  • Reduced blood platelets, which increases risk of bleeding or bruising
  • Psoriasis

If you experience any of the following non-serious side effects contact your doctor and/or seek medical advice:

Uncommon: (may affect up to 1 in 100 people)

Irritability, nervousness, restlessness, insomnia, abnormal dreams, nightmares, anxiety, migraine, headache, lethargy (tiredness, lack of energy), restlessness associated with increased activity, dizziness, tiredness, high blood pressure, upper abdominal pain, indigestion, mouth ulceration, dry mouth, nausea, changes in the composition of your blood which could cause yellowing of the skin or eyes, inflammation of the skin, night sweats, itching, rash, dry skin, pain in extremities, menopausal symptoms, feeling of weakness, excretion of glucose in the urine, excess proteins in the urine, abnormal liver function and weight increase.

Rare: (may affect up to 1 in 1000 people)

Shingles, high level of fatty molecules in the blood, low serum calcium levels in the blood, low sodium levels in the blood, altered mood, aggression, agitation, crying, stress symptoms, early morning awakening, increased sex drive, depressed mood, memory impairment, disturbance in attention, dreamy state, restless legs syndrome, poor quality sleep, ‘pins and needles’ feeling, watery eyes, dizziness when standing or sitting, hot flushes, acid reflux, stomach disorder, blistering in the mouth, tongue ulceration, stomach upset, vomiting, abnormal bowel sounds, wind, excess saliva production, bad breath, abdominal discomfort, gastric disorder, inflammation of the stomach lining, eczema, skin rash, hand dermatitis, itchy rash, nail disorder, arthritis, muscle spasms, neck pain, night cramps, prolonged erection that might be painful, inflammation of the prostate gland, tiredness, pain, thirst, passing large volumes of urine, urinating during the night, increased liver enzymes, abnormal blood electrolytes and abnormal laboratory tests.

Frequency not known: (cannot be established from the available data)

Hypersensitivity reaction, swelling of mouth or tongue, swelling of the skin and abnormal milk secretion.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Civasta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after ‘EXP’. The expiry date refers to the last day of that month.

Do not store above 25°C. Store in the original package in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Civasta contains
  • The active substance is melatonin. Each prolonged-release tablet contains 2 mg melatonin.
  • The other ingredients are ammonio methacrylate copolymer type B, calcium hydrogen phosphate dihydrate, lactose monohydrate (see section 2 “Civasta contains lactose monohydrate”), silica (colloidal anhydrous), talc and magnesium stearate.

What Civasta looks like and contents of the pack

Civasta 2 mg prolonged-release tablets are white to off-white, biconvex, oval tablets, 5.2 x 10 mm, with ‘A6’ debossed on one side.

Civasta is available in blister packs of 30 prolonged-release tablets.

Marketing Authorisation Holder
Neuraxpharm UK Limited
Unit 12 Farnborough Business Centre
Eelmoor Road
Farnborough
Hampshire
GU14 7XA
United Kingdom

Manufacturer
Balkanpharma-Dupnitsa AD
3 Samokovsko Shosse Str.
Dupnitza 2600
Bulgaria

or

neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert-Straße 23
40764 Langenfeld
Germany

This leaflet was last revised in April 2022.

Is this leaflet hard to see or read? Phone 0118 211 4039 for help.

Neuraxpharm UK Ltd
Company image
Address
Neuraxpharm UK Ltd, Suite 2, Arlington Flex, Third Floor, Building 1420, Arlington Business Park, Theale, Reading, Berkshire, RG7 4SA, UK
Telephone
0118 211 4039
E-mail
[email protected]
Adverse event reporting email
[email protected]
Medical Information e-mail
[email protected]